Member LoginDividend CushionValue Trap
|
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
Latest
Valuentum Commentary
Apr 4, 2017
Can Vertex Pharmaceuticals Dominate the Race to Treat Cystic Fibrosis?
Cystic Fibrosis is a rare disease that afflicts an estimated seventy-five thousand patients worldwide. Vertex Pharmaceuticals is the first to market with a combination treatment to treat a portion of the overall patient population. Will Vertex win the race to bring forth a triple therapy to treat the vast majority of those afflicted? Nov 21, 2016
Dividend Increases/Decreases for the Week Ending November 18
Let's take a look at companies raising/lowering their dividends this week. Nov 16, 2016
Pharma, Biotech and How to Consider Investing In It
The Valuentum analyst team digs deep into recent trends in big pharma and biotech from the lofty pricing of drugs to political and competitive pressures to ETF considerations and beyond. ~10 mins. Aug 12, 2016
Industrials Empty Tool Box Amid Tough Operating Environment
Let’s take a look at calendar second-quarter reports for a variety of industrial entities. Nov 23, 2015
Dividend Increases/Decreases for the Week Ending November 20
Let's take a look at companies raising/lowering their dividends this week. Jun 22, 2014
Valuentum Economic Castle™ Rating Update
Members should expect the initial Economic Castle™ ratings. Nov 22, 2013
Dividend Increases/Decreases for the Week Ending November 22
Let's take a look at dividend increases/decreases for the week ending November 22. Sep 29, 2013
Keeping Some Dry Powder
Equity valuations have become stretched with the forward price-to-earnings multiple on S&P 500 companies now greater than both its 5-year and 10-year averages. We don't think this bodes well for indexers, buy-and-hold strategies, or those focused purely on asset allocation. We're keeping some dry powder. Latest News and Media The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|
